In the December (1) issue of Bone Marrow Transplantation, Arance et al 1 reported a case of catheter-related bacteremia in the early post-PBSCT period by the rare nonglucose fermenting gram negative bacillus (NGFGNB) CDC group IV c-2. We would like to comment briefly on this observation.
This bacterium has been rarely reported in human infections, and besides the seven cases cited by Arance et al, 1 there have been six other published cases.
2,3 Ten of these 13 infections were catheter-related bacteremias, and none of the patients died or suffered severe morbidity from the infection. These clinical characteristics are shared by many of the growing bacteremias by other NGFGNB in patients with cancer. [4] [5] [6] From January 1993 to December 1997 in our adult Hematology and Stem Cell Transplant Ward, 14 patients suffered bacteremia from Pseudomonas aeruginosa and 46 had blood infections by other NGFGNB (including three cases of CDC group IV c-2 bacteremia), while 60 had bacteremia from an enterobacterium. The three cases of bacteremia by CDC group IV c-2 from our series are summarized in Table 1 . These three infections occurred within a 12-month period in the inpatient ward and were catheter-related bacteremias which developed during the early neutropenic phase after autologous PBSCT for AML, CML and lymphoma (one case each). One episode was cured with antibiotics (ceftazidime plus ciprofloxacin) while the other two required removal of the catheter due to antibiotic-refractory bacteremia, similar to Arance's case. The three isolates had nearly identical antibiotic sensitivities, being susceptible in vitro to amoxicillin plus clavulamate, ticarcillin, imipenem, second and third generation cephalosporins, fluoroquinolones and trimethoprim/ sulphamethoxazole and were resistant to aztreonam and all the aminoglycosides, a feature consistent with previous reports.
1-3 Additionally, two of the three isolates were resistant to meropenem. Cipro bactermia removal M = male; F = female; CML = chronic myelogenous leukemia; AML = acute myelogenous leukemia; CY = cyclophosphamide; BU = busulphan; CBV = cyclophosphamide, BCNU, VP-16; APBSCT = autologous peripheral blood stem cell transplantation; ANC = absolute neutrophil count; BC = blood cultures; IMP = imipenem; Cipro = ciprofloxacin.
The ecology of CDC IV c-2 is poorly documented, as with other NGFGNB. However, it appears to be a teluric and hydrophylic bacterium, and seven of 37 isolates identified by the CDC derived from water. 7 More interestingly a recent report of an outbreak of five infections in children with cancer demonstrated the common origin of all five strains by DNA analysis.
3 Unfortunately, we did not perform DNA studies to determine the genotypic relationship of all three strains and the almost identical antibiotic sensitivity patterns do not necessarily indicate their common origin. Routine environmental cultures were performed without isolating the micro-organism from any source, as occurred in the previously cited study. In conclusion, CDC IV c-2 must be added to the growing list of nosocomial gram-negative bacterial infections in patients with cancer, although it is rare and appears to have a low level of pathogenicity. 
Colostrum and severe gut GVHD
Treatment of severe gut graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) remains problematic even though there have been many advances in immunosuppressive therapy. Recently we have treated nine patients who suffered from severe gut GVHD: large volumes of watery and bloody stool, paralytic ileus and severe abdominal pain. We gave them colostrum for the treatment of severe gut GVHD and six out of nine showed clinical improvement. A dose of colostrum was set at 20 ml daily and given for 5 consecutive days. Colostrum was obtained from random donors. Clinical data of these nine patients are summarized in Table 1 . Two of them (UPN 151 and 157) were not evaluated because of poor compliance. Rectal biopsies were performed in six cases (UPN 147, 151, 159, 164, 166 and 173) and histological findings were compatible with enteric GVHD in all cases. Thrombotic microangiopathy combined with GVHD was proven in UPN 151 and also CMV infection was confirmed by in situ hybridization in UPN 159. One typical case (UPN 147) is presented. This patient was diagnosed with B-precursor ALL (CD10 negative) when she was 3 months old and transplanted from an unrelated HLA-matched donor in second complete remission when she was 1 year old. Conditioning consisted of TBI (12 Gy), etoposide (60 mg/kg) and cyclophosphamide (120 mg/kg). FK506 and methylprednisolone (mPSL) were used for GVHD prophylaxis. Ganciclovir was administered from days −8 to −1 because she was CMVseropositive. Engraftment was prompt. Neutrophils rose to 0.5 × 10 9 /l on day 14. Platelets rose to 20 × 10 9 /l on day 17. Reticulocytes reached 1% on day 57. Complete chimerism was confirmed by VNTR on day 47.
She developed grade III acute GVHD. A rash appeared on day 15 followed by bloody diarrhea complicated by paralytic ileus. The peak value of TB was 4.4 mg/dl on day 34. A rectal biopsy was performed and histological findings were compatible with acute GVHD. CMV infection was not detected by in situ hybridization. Symptoms of gut GVHD persisted in spite of high-dose mPSL (pulse therapy), methotrexate and anti-thymocyte globulin (ATG). We therefore decided to use colostrum and low-dose etoposide (VP16) as a systemic immunosuppressive agent. Colostrum obtained from random donors was administered orally at 20 ml/day for 5 consecutive days. Her gut GVHD disappeared soon after the colostrum therapy as shown in Figure 1 . In addition, the liver and skin GVHD improved.
It is well known that breast feeding plays an important role for babies in preventing infection and in developing the digestive system. Human milk, especially colostrum, contains many materials such as cytokines (TGF␤, EGF, etc) and sIgA.
1 The present trial is still preliminary and the efficacy of colostrum therapy for gut GVHD should be confirmed in more cases. In the same setting oral immunoglobulin may be an alternative choice.
2 However, in our
